Circassia is a world-class specialty biopharmaceutical business focused on allergy and respiratory disease. The Company has an established commercial infrastructure, marketed products, a pipeline of near-term therapies and a portfolio of next generation treatments targeting multi-$billion market opportunities. Circassia sells its novel, market-leading products for asthma management directly to allergy / asthma specialists in the United States and Germany. Its products are also promoted in a number of other countries by the Company’s international network of partners.
Circassia’s broad-based development pipeline includes a range of treatments for allergy and respiratory disease. Circassia’s most advanced next-generation immunotherapy is currently in phase III testing for cat allergy, and is the first in a new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). Three other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies. Circassia’s lead asthma product targets substitution of GSK’s FLIXOTIDE® pMDI, and UK approval is expected in December 2015. Circassia anticipates two further product filings in 2016, targeting direct substitution of SERETIDE® pMDI and SEREVENT® pMDI. The Company is also developing a number of novel treatments, including a fixed dose ‘triple’ combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

Company Growth (employees)
Oxford, GB
Size (employees)
204 (est)
Circassia was founded in 2006 and is headquartered in Oxford, GB

Key People at Circassia

Steven Harris

Steven Harris

Charles Swingland

Charles Swingland

Deputy Chairman and General Counsel

Circassia Office Locations

Circassia has offices in Oxford, Chicago and Solna
Oxford, GB (HQ)
The Oxford Science Park
Solna, SE
18 Råsundavägen
Chicago, US
101 North Wacker Drive Suite 100

Circassia Data and Metrics

Circassia Financial Metrics


Net income (FY, 2015)

(1 k)

Market capitalization (20-Jul-2017)

253.3 m

Closing share price (20-Jul-2017)

Circassia's current market capitalization is £253.3 m.
GBPFY, 2013FY, 2014FY, 2015

Pre tax profit

(295 k)(3 k)

Net Income

(269 k)(2 k)(1 k)
GBPFY, 2013FY, 2014FY, 2015

Accounts Receivable

27 k1 k

Current Assets

27 k1 k

Total Assets

27 k1 k

Accounts Payable

21 k

Current Liabilities

21 k

Total Liabilities

2.3 m2.3 m2.3 m

Retained Earnings

(269 k)(2 k)(1 k)

Total Equity

(2.3 m)(2.3 m)(2.3 m)

Financial Leverage

0 x0 x
GBPFY, 2013FY, 2014FY, 2015

Income Taxes Paid

26 k1 k(1 k)

Circassia Market Value History

Traffic Overview of Circassia

Circassia News and Updates

Circassia share price tanks by 65 per cent as allergy treament fails trial

Pharmaceutical company Circassia has lost more than half its value this morning after its experimental cat allergy treatment failed in a late-stage trial. The firm's stock was down by 64.85 per cent in early trading.  Circassia said the study showed that both the treatment regimens and the pla…

Circassia Company Life and Culture

You may also be interested in